Follow last change Apr 2019 re-read 3 minutes ago

IC01

Developed for: cancer · digestive system cancer
Investigated by: Hangzhou Converd Co., Ltd. · The Second Hospital of Jia Xing · The Second People's Hospital of Yibin

today NCT03472352 · Ph 1 NCT03474861 · Ph 1

201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03472352	Apr 2018 → Apr 2019	cancer	Hangzhou Converd Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT03474861	Apr 2018 → Apr 2019	digestive system cancer	Hangzhou Converd Co., Ltd.	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	IC01	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03474861 ↗ 1 NCT03472352 ↗
Modality	Cell therapy	“immune cells (IC01)” NCT03472352 ↗